GlassScriptPhysician profile
Eric J Thomas
NPI 1649290289
$10,936.10
in general payments reported to CMS, 2019-2025
23 companies · $2,762 in 2025
The $2,762 reported for 2025 was more than what 83% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $261 · 2021: $748 · 2022: $1,646 · 2023: $2,501 · 2024: $2,852 · 2025: $2,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,105 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,104.59 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,399.53 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,057.66 | 2020-2025 | |
| Amgen INC. | $888.84 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $841.45 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $781.15 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $656.63 | 2020-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $484.57 | 2020-2025 | Cabtreo, Jublia, Siliq |
| Leo Pharma INC. | $464.14 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Pfizer INC. | $434.83 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $420.61 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $357.12 | 2020-2025 | Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $211.05 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $202.71 | 2023-2024 | Sotyktu |
| Ucb, INC. | $195.21 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $178.37 | 2023-2024 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $130.96 | 2022-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.53 | 2024-2025 | Spevigo |
| Epi Health, LLC | $40.97 | 2021-2022 | |
| Galderma Laboratories, L.P. | $28.85 | 2025 | Nemluvio |
| Astellas Pharma US INC | $20.26 | 2024 | Izervay |
| Verrica Pharmaceuticals INC. | $16.74 | 2025 | Ycanth |
| Almirall LLC | $13.70 | 2021 | |
| Vyne Pharmaceuticals INC. | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.